These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35574003)

  • 1. Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems.
    Wang H; Zhou Y; Wang Y; Cai T; Hu Y; Jing T; Ding B; Su X; Li H; Ma J
    Front Endocrinol (Lausanne); 2022; 13():791439. PubMed ID: 35574003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
    Krajnc M; Kravos Tramšek NA
    Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
    Umpierrez GE; O'Neal D; DiGenio A; Goldenberg R; Hernandez-Triana E; Lin J; Park CY; Renard E; Kovatchev B
    Diabetes Obes Metab; 2017 Sep; 19(9):1317-1321. PubMed ID: 28256054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
    Su JB; Wang XQ; Chen JF; Wu G; Jin Y
    Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with glycemic variability in children with type 1 diabetes mellitus based on flash glucose monitoring system.
    Zhang L; Guo K; Xu Y; Bai J; Ma Y; Fu L; Liu J; Hu K; Li X; Jiang H; Yang L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 47(4):462-468. PubMed ID: 35545341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
    Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
    Front Public Health; 2022; 10():990281. PubMed ID: 36091534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prepregnancy care in women with type 1 diabetes improves HbA
    Perea V; Giménez M; Amor AJ; Bellart J; Conget I; Vinagre I
    Diabetes Res Clin Pract; 2019 Aug; 154():75-81. PubMed ID: 31271810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.
    Hanefeld M; Koehler C; Hoffmann C; Wilhelm K; Kamke W; Gerstein H
    Diabet Med; 2010 Feb; 27(2):175-80. PubMed ID: 20546261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?
    Inzucchi SE; Umpierrez G; DiGenio A; Zhou R; Kovatchev B
    Diabetes Res Clin Pract; 2015 Apr; 108(1):179-86. PubMed ID: 25661664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
    Zhou J; Zheng F; Guo X; Yang H; Zhang M; Tian H; Guo L; Li Q; Mo Y; Jia W
    Diabetes Metab Res Rev; 2015 Oct; 31(7):725-33. PubMed ID: 25952634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
    Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
    Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
    Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial.
    Ajjan RA; Jackson N; Thomson SA
    Diab Vasc Dis Res; 2019 Jul; 16(4):385-395. PubMed ID: 31271312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes.
    Christensen MB; Gæde P; Hommel E; Gotfredsen A; Nørgaard K
    Diabetes Metab; 2020 Feb; 46(1):61-65. PubMed ID: 30796973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous glucose monitoring systems for type 1 diabetes mellitus.
    Langendam M; Luijf YM; Hooft L; Devries JH; Mudde AH; Scholten RJ
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD008101. PubMed ID: 22258980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the target value of the coefficient of variation by continuous glucose monitoring in Chinese people with diabetes.
    Mo Y; Ma X; Lu J; Shen Y; Wang Y; Zhang L; Lu W; Zhu W; Bao Y; Zhou J
    J Diabetes Investig; 2021 Jun; 12(6):1025-1034. PubMed ID: 33119969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin during pregnancy, labour and delivery.
    de Valk HW; Visser GH
    Best Pract Res Clin Obstet Gynaecol; 2011 Feb; 25(1):65-76. PubMed ID: 21186142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.